Suppr超能文献

体质指数和腰臀比联合雌孕激素受体状态对中国北方和东部地区乳腺癌发病风险的影响:病例对照研究结果及其对化学预防的意义。

Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.

机构信息

Department of Breast Surgery, the Second Hospital of Shandong University, Jinan, Shandong Province, People's Republic of China.

Department of Breast Surgery, Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.

出版信息

Oncologist. 2017 Dec;22(12):1431-1443. doi: 10.1634/theoncologist.2017-0148. Epub 2017 Sep 14.

Abstract

BACKGROUND

Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk. Body mass index (BMI) and waist/hip ratio (WHR) have demonstrated different effects on breast cancer risk in relation to estrogen receptor (ER) status, but the results have been inconsistent. Furthermore, the situation in Chinese women remains unclear.

MATERIALS AND METHODS

We conducted a case-control study including 1,439 breast cancer cases in Northern and Eastern China. Both ER and progesterone receptor (PR) statuses were available for 1,316 cases. Associations between body size-related factors and breast cancer risk defined by receptor status were assessed by multiple polytomous unconditional logistic regression analysis.

RESULTS

Body mass index and WHR were positively associated with overall breast cancer risk. Body mass index was positively associated with both ER+/PR positive (PR+) and ER negative (ER-)/PR negative(PR-) subtype risks, although only significantly for ER+/PR+ subtype. Waist-hip ratio was only positively correlated with ER-/PR- subtype risk, although independent of BMI. Body mass index was positively associated with risk of ER+/PR+ and ER-/PR- subtypes in premenopausal women, whereas WHR was inversely correlated with ER+/PR- and positively with ER-/PR- subtype risks. Among postmenopausal women, WHR >0.85 was associated with increased risk of ER-/PR- subtype.

CONCLUSION

Both general and central obesity contribute to breast cancer risk, with different effects on specific subtypes. General obesity, indicated by BMI, is more strongly associated with ER+/PR+ subtype, especially among premenopausal women, whereas central obesity, indicated by WHR, is more specific for ER-/PR- subtype, independent of menopausal status. These results suggest that different chemoprevention strategies may be appropriate in selected individuals.

IMPLICATIONS FOR PRACTICE

The results of this study suggest that general and central obesity may play different roles in different breast cancer subtypes, supporting the hypothesis that obesity affects breast carcinogenesis via complex molecular interconnections, beyond the impact of estrogens. The results also imply that different chemoprevention strategies may be appropriate for selected individuals, highlighting the need to be particularly aware of women with a high waist/hip ratio but normal body mass index. Given the lack of any proven pharmacologic intervention for estrogen receptor negative breast cancer, stricter weight-control measures may be advised in these individuals.

摘要

背景

肥胖是雌激素受体(ER)阳性(ER+)乳腺癌风险药物干预的一个考虑因素。体重指数(BMI)和腰臀比(WHR)已证明在与雌激素受体(ER)状态相关的乳腺癌风险方面具有不同的影响,但结果不一致。此外,中国女性的情况尚不清楚。

材料和方法

我们在中国北方和东部进行了一项病例对照研究,包括 1439 例乳腺癌病例。1316 例病例均有 ER 和孕激素受体(PR)状态。通过多分类非条件逻辑回归分析评估与体型相关因素与受体状态定义的乳腺癌风险之间的关联。

结果

BMI 和 WHR 与总体乳腺癌风险呈正相关。BMI 与 ER+/PR+(PR+)和 ER 阴性(ER-)/PR 阴性(PR-)亚型风险均呈正相关,尽管仅与 ER+/PR+ 亚型显著相关。WHR 仅与 ER-/PR- 亚型风险呈正相关,而与 BMI 无关。BMI 与绝经前妇女的 ER+/PR+和 ER-/PR- 亚型风险呈正相关,而 WHR 与 ER+/PR-和 ER-/PR- 亚型风险呈负相关。绝经后妇女中,WHR>0.85 与 ER-/PR- 亚型风险增加相关。

结论

全身性和中心性肥胖均与乳腺癌风险相关,对特定亚型的影响不同。BMI 表示的全身性肥胖与 ER+/PR+ 亚型的相关性更强,尤其是在绝经前妇女中,而 WHR 表示的中心性肥胖与 ER-/PR- 亚型更为特异,与绝经状态无关。这些结果表明,在选定的个体中,可能需要采用不同的化学预防策略。

实践意义

本研究结果表明,全身性和中心性肥胖可能在不同的乳腺癌亚型中发挥不同的作用,支持肥胖通过复杂的分子相互联系影响乳腺癌发生的假说,而不仅仅是通过雌激素的影响。结果还表明,针对特定个体,可能需要采用不同的化学预防策略,突出了需要特别注意腰臀比高但 BMI 正常的女性。由于目前尚无针对雌激素受体阴性乳腺癌的药物干预措施,因此这些个体可能需要更严格的体重控制措施。

相似文献

4
Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
Int J Obes (Lond). 2012 Mar;36(3):431-9. doi: 10.1038/ijo.2011.66. Epub 2011 Mar 22.
8
Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
Breast Cancer Res. 2019 Apr 3;21(1):48. doi: 10.1186/s13058-019-1129-9.

引用本文的文献

1
[Factors Influencing Progression on the Ultrasound BI-RADS Categories: An Analysis Based on a Breast Cancer Screening Cohort].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Nov 20;55(6):1550-1556. doi: 10.12182/20241160508.
2
The relationship between central obesity and risk of breast cancer: a dose-response meta-analysis of 7,989,315 women.
Front Nutr. 2023 Nov 9;10:1236393. doi: 10.3389/fnut.2023.1236393. eCollection 2023.
4
The underexplored links between cancer and the internal body climate: Implications for cancer prevention and treatment.
Front Oncol. 2022 Dec 22;12:1040034. doi: 10.3389/fonc.2022.1040034. eCollection 2022.
7
Triglyceride-Glucose Index Is Not Associated With Lung Cancer Risk: A Prospective Cohort Study in the UK Biobank.
Front Oncol. 2021 Nov 17;11:774937. doi: 10.3389/fonc.2021.774937. eCollection 2021.
9
Breast adipose regulation of premenopausal breast epithelial phenotype involves interleukin 10.
J Mol Endocrinol. 2021 Sep 9;67(4):173-188. doi: 10.1530/JME-21-0100.

本文引用的文献

1
The Association Between Body Size and Breast Cancer in Han Women in Northern and Eastern China.
Oncologist. 2016 Nov;21(11):1362-1368. doi: 10.1634/theoncologist.2016-0147. Epub 2016 Aug 5.
3
Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.
Oncologist. 2016 Apr;21(4):404-17. doi: 10.1634/theoncologist.2015-0351. Epub 2016 Feb 10.
4
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer.
Cancers (Basel). 2015 Oct 26;7(4):2147-68. doi: 10.3390/cancers7040883.
5
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.
CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42. doi: 10.3322/caac.21320. Epub 2015 Oct 29.
6
Molecular cancer prevention: Current status and future directions.
CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Epub 2015 Aug 18.
7
Obesity in breast cancer--what is the risk factor?
Eur J Cancer. 2015 Apr;51(6):705-20. doi: 10.1016/j.ejca.2015.01.057. Epub 2015 Mar 3.
8
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.
9
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
10
Relationship between urinary sodium excretion and pioglitazone-induced edema.
J Diabetes Investig. 2010 Oct 19;1(5):208-11. doi: 10.1111/j.2040-1124.2010.00046.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验